MJardin Group Granted Cannabis Cultivation License by Health Canada for Nova Scotia Facility

DENVER–(BUSINESS WIRE)–MJardin Group, Inc. (“MJardin” or the “Company”)
(CSE:MJAR), a leader in cannabis management, is pleased to announce that
the recently
opened cultivation and extraction facility in Lower Sackville, Nova
Scotia owned by AtlantiCann Medical Inc. (“AMI”), in which
MJardin has a 50% equity interest, has been granted a license by Health
Canada for cannabis cultivation.

The new state-of-the-art, 48,000 square foot cultivation and extraction
facility has a production capacity of 6,000 kg per year, with expansion
planned for an additional 20,000 square feet by the end of 2019. AMI
intends to seek GMP certification for the facility in 2019.

“Since federal legalization in October, the Canadian cannabis market has
struggled to meet strong consumer demand due to supply shortages,” said
Rishi Gautam, Chairman and Chief Executive Officer of MJardin Group. “We
are very pleased to receive our cultivation license from Health Canada
and will leverage our decade-long experience in cannabis cultivation to
assist in bringing significant supply online to meet growing consumer
demand for high quality medicinal and adult-use cannabis products.”

“Our newly granted cultivation license is an important milestone and a
key operational development for AMI. We are proud of our growing
footprint in Atlantic Canada with the support of MJardin. With the first
harvest at our state-of-the-art facility expected to be complete in the
spring of 2019, we are well positioned to provide innovative, premium
cannabis products to help patients cope with their ailments,” said
Christine Halef, President of AtlantiCann Medical Inc.

About MJardin Group

MJardin is a global cannabis management platform with extensive
experience in cultivation, processing, distribution and retail. For over
10 years, MJardin has refined cultivation methodologies, developed state
of the art facilities and implemented vertical integration for and on
behalf of license owners. As a well-capitalized organization, MJardin
continues to pursue strategic expansion and M&A opportunities across
global legal cannabis markets. MJardin is based in Denver Colorado, with
offices in Toronto, Canada and Barcelona, Spain. For more information,
please visit www.mjardin.com.

About AtlantiCann Medical Inc.

AtlantiCann Medical Inc. (AMI) was founded in 2013 with an application
submitted under the MMPR program with the primary objective of advancing
the uses of medicinal cannabis. Since then the 48,000 square foot
facility, located in Lower Sackville, NS has completed construction and
received a cultivation license from Health Canada. MJardin, a company
with extensive experience in producing cannabis, is a 50% equity owner
in AMI. With their combined knowledge and experience in cultivation and
pharmaceuticals, they will strive to provide excellence, reliability and
innovation in this burgeoning sector.

The CSE has not in any way passed upon the merits of the matters
contained in this press release.

This news release does not constitute an offer to sell or a
solicitation of an offer to sell any of the securities in the United
States. The securities have not been and will not be registered under
the United States Securities Act of 1933, as amended (the “U.S.
Securities Act”) or any state securities laws and may not be offered
or sold within the United States or to U.S. Persons unless registered
under the U.S. Securities Act and applicable state securities laws or an
exemption from such registration is available.

Forward-Looking Information

This news release contains forward-looking information based on
current expectations. Statements about, among other things, future
developments and the business and operations of MJardin or the Nova
Scotia facility, the growth of or global footprint and our intentions to
leverage our scale for continued organic growth and to pursue strategic
investments are all forward-looking information. These statements
should not be read as guarantees of future performance or results. Such
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by such statements. Such
factors include, but are not limited to: our ability to identify and
pursue growth, financing and other strategic objectives, and the
regulatory and economic environments in the jurisdictions we operate or
intend to operate or investment in. Although such statements are
based on management’s reasonable assumptions at the date such statements
are made, there can be no assurance that the proposed acquisition will
occur and that such forward-looking information will prove to be
accurate, as actual results and future events could differ materially
from those anticipated in such forward-looking information. Accordingly,
readers should not place undue reliance on the forward-looking
information. MJardin assumes no responsibility to update or
revise forward-looking information to reflect new events or
circumstances unless required by applicable law.

Contacts

Media:
Cory Ziskind
ICR
646-277-1232
cory.ziskind@icrinc.com

Investor:
Ali Mahdavi
Capital Markets & Investor
Relations
416-962-3300
Ali.mahdavi@mjardin.com

Frank Knuettel II, 720-613-4019
Chief Strategy Officer
Frank.Knuettel@MJardin.com